Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile?
Michelangelo Russillo(National Cancer Institute), Alessandra Fabi(Agostino Gemelli University Polyclinic), Francesco Cognetti(Apple (Israel)), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Anna Di Benedetto, Marcella Mottolese, Paola Papaldo(Cancer Institute (WIA)), Giulio Metro(University of Perugia)
Cited by 4
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma
|Journal of Clinical Oncology|2020|226